Baird served as a co-manager on this transaction.
AboutUltragenyx Pharmaceuticals Inc. (“Ultragenyx” or the “Company”) (NASDAQ: RARE) recently completed a follow-on offering of 3,450,000 shares of common stock at a price of $54.00 per share, generating gross proceeds of approximately $186 million. The Company intends to use the net proceeds from the offering to increase investment in early-stage translational research capabilities, in order to identify and develop potential new products for the pipeline, as well as to initiate efforts to establish commercial operations for named-patient sales and potential future marketing authorizations.
Ultragenyx is a clinical-stage biopharmaceutical company committed to bringing to market novel products for the treatment of rare and ultra-rare diseases, with a focus on serious, debilitating genetic diseases. Founded in 2010, the company has built a diverse portfolio of product candidates with the potential to address diseases for which the unmet medical need is high, the biology for treatment is clear, and for which there are no approved therapies. The Company is headquartered in Novato, California.
For additional information about this transaction, please contact:
- January 2015
- Ultragenyx Pharmaceuticals Inc.
- Target Location
- North America